gap junction protein beta 2Genealiases: BAPS · CX26 · DFNA3 · DFNA3A · DFNB1 · DFNB1A
Q-omics provides the consensus-scored GJB2 profile across patient tissues and cancer cell-line models. GJB2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GJB2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GJB2 RNA expression shows 18,752 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUAD, KIRC, and PDAC as cancer lineages where GJB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GJB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GJB2 survival associations across molecular data types. GJB2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GJB2 RNA expression–survival associations across cancer types. High GJB2 expression shows unfavorable associations in LUAD, ACC, CESC, OV, PAAD and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for GJB2 RNA expression.
This table summarizes GJB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GJB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GJB2 shows lower tumor expression in KICH and higher tumor expression in KIRC, LUSC, LUAD, BLCA and BRCA. The KIRC box plot shows higher GJB2 RNA expression in tumor versus normal tissue (log2 FC = +1.762, t-test p < 0.001).
This table shows molecular features associated with GJB2 in patient tissues and cancer cell lines. In patient samples, GJB2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GJB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and URINARY_TRACT.
